ATRN-354

ATRN-354 is a **second-generation small molecule inhibitor of ataxia telangiectasia and Rad3-related protein (ATR)**, developed initially by Atrin Pharmaceuticals and now under Aprea Therapeutics[1][3][5][9][11]. Its mechanism of action involves *selective inhibition of ATR kinase*, a key regulator in the DNA damage response (DDR) pathway, which is particularly relevant in oncology for exploiting synthetic lethality in tumor cells with defective DNA repair mechanisms[1][3][5][9][11]. The compound is designed with potentially improved potency and pharmacokinetics relative to earlier ATR inhibitors. It is under preclinical development for solid tumors and has not yet reached clinical trial phases as of the latest update[1][3][5][9][11].

Brand names

ATRN-354ATRN354ATRN 354

Other names

ATRN-354ATRN354ATRN 354